Cargando…

Transient receptor potential V1 modulates neuroinflammation in Parkinson’s disease dementia: Molecular implications for electroacupuncture and rivastigmine

OBJECTIVE(S): Parkinson’s disease (PD) is a common progressive neurodegeneration disease. Its incidence increases with age and affects about 1% of people over 60. Incidentally, transient receptor potential V1 (TRPV1) and its relation with neuroinflammation in mouse brain has been widely reported. MA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Sheng-Ta, Wei, Tzu-Hsuan, Yang, Yu-Wan, Lu, Ming-Kuei, San, Shao, Tsai, Chon-Haw, Lin, Yi-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mashhad University of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769514/ https://www.ncbi.nlm.nih.gov/pubmed/35096291 http://dx.doi.org/10.22038/IJBMS.2021.56156.12531

Ejemplares similares

The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review
por: Tsai, Sheng-Ta, et al.
Publicado: (2020)

Rivastigmine for the treatment of dementia associated with Parkinson’s disease
por: Reingold, Jennifer L, et al.
Publicado: (2007)

Paired Associative Electroacupuncture and Transcranial Magnetic Stimulation in Humans
por: Huang, Yi, et al.
Publicado: (2019)

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
por: Oh, Yoon-Sang, et al.
Publicado: (2015)

Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson's Dementia Complex: New Aspects for This Riddle
por: Moretti, Rita, et al.
Publicado: (2017)

Biomarker of Neuroinflammation in Parkinson’s Disease
por: Liu, Tsai-Wei, et al.
Publicado: (2022)

Rivastigmine in Chinese patients with subcortical vascular dementia
por: Mok, Vincent, et al.
Publicado: (2007)

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
por: Kandiah, Nagaendran, et al.
Publicado: (2017)

Impairments in face discrimination and emotion recognition are related to aging and cognitive dysfunctions in Parkinson’s disease with dementia
por: Ho, Mary Wen-Reng, et al.
Publicado: (2020)

The Rehabilitative Effect of Archery Exercise Intervention in Patients with Parkinson's Disease
por: Chen, Chiu-Ying, et al.
Publicado: (2023)

Cerebellum to motor cortex paired associative stimulation induces bidirectional STDP-like plasticity in human motor cortex
por: Lu, Ming-Kuei, et al.
Publicado: (2012)

Impaired Cerebellum to Primary Motor Cortex Associative Plasticity in Parkinson’s Disease and Spinocerebellar Ataxia Type 3
por: Lu, Ming-Kuei, et al.
Publicado: (2017)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia
por: Giorgi, Filippo Sean, et al.
Publicado: (2020)

Neuroinflammation and protein pathology in Parkinson’s disease dementia
por: Kouli, Antonina, et al.
Publicado: (2020)

The neuromuscular responses in patients with Parkinson’s disease under different conditions during whole-body vibration training
por: Chang, Chia-Ming, et al.
Publicado: (2022)

VBM Reveals Brain Volume Differences between Parkinson’s Disease and Essential Tremor Patients
por: Lin, Ching-Hung, et al.
Publicado: (2013)

Investigation of Motor Cortical Plasticity and Corticospinal Tract Diffusion Tensor Imaging in Patients with Parkinsons Disease and Essential Tremor
por: Lu, Ming-Kuei, et al.
Publicado: (2016)

Convergent Associative Motor Cortical Plasticity Induced by Conditional Somatosensory and Motor Reaction Afferents
por: Huang, Yi, et al.
Publicado: (2020)

The Effects of Rivastigmine on Neuropsychiatric Symptoms in the Early Stages of Parkinson's Disease: A Systematic Review
por: Reilly, Siobhan, et al.
Publicado: (2023)

Bereitschaftspotential in Multiple System Atrophy
por: Yang, Yi-Chien, et al.
Publicado: (2021)

Acupuncture reduced the medical expenditure in migraine patients: Real-world data of a 10-year national cohort study
por: Tsai, Sheng-Ta, et al.
Publicado: (2020)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

Acquired Localized Hypertrichosis Induced by Rivastigmine
por: Imbernón-Moya, Adrian, et al.
Publicado: (2016)

Effectiveness of the 10 cm(2) Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
por: Chang, Chiung-Chih, et al.
Publicado: (2021)

The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen
por: Henderson, Emily J, et al.
Publicado: (2013)

A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routine clinical setting
por: Nazir, Ejaz, et al.
Publicado: (2010)

Peripheral trauma and risk of dystonia: What are the evidences and potential co-risk factors from a population insurance database?
por: Macerollo, Antonella, et al.
Publicado: (2019)

Degraded Impairment of Emotion Recognition in Parkinson's Disease Extends from Negative to Positive Emotions
por: Lin, Chia-Yao, et al.
Publicado: (2016)

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

Effects of rivastigmin tartarat in the therapy of patients with schizophrenia
por: Djordjevic, Snezana, et al.
Publicado: (2010)

Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine
por: Gao, Guorui, et al.
Publicado: (2018)

Treatment of pediatric antimuscarinic delirium with oral rivastigmine
por: Yakey, Brandtly, et al.
Publicado: (2023)

Early electroacupuncture treatment ameliorates neuroinflammation in rats with traumatic brain injury
por: Tang, Wei-Chen, et al.
Publicado: (2016)

Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan
por: Chang, Chee-Jen, et al.
Publicado: (2018)

Neuroinflammation, AD, and Dementia
por: Reale, Marcella, et al.
Publicado: (2010)

Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow‐up
por: van Mierlo, Tom J. M., et al.
Publicado: (2021)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_vklkobnl07b6hvabobo3c3b4vr